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OBJECTIVE: The purpose of this study was to identify risk factors as-
sociated with striae gravidarum (SG).
STUDY DESIGN: A cross-sectional study of 112 primiparous women
delivering at a private teaching hospital was conducted. Participants
were assessed during the immediate postpartum period for evidence of
SG. Presence and severity of SG were compared to characteristics of
women using t tests and Chi-square tests.
RESULTS: Sixty percent of the study participants had developed SG.
Women who developed SG were signiﬁcantly younger (26.5  4.5 vs
30.5  4.6; P  .001) and had gained signiﬁcantly more weight dur-
ing pregnancy (15.6  3.9 vs 38.4 kg  2.7; P  .001). Birthweight
(BW), gestational age at delivery, and family history of SG were asso-
ciated with moderate/severe SG.
CONCLUSION: Maternal age and weight gain during pregnancy are as-
sociated with SG. BW, family history of SG, and gestational age at
delivery are associated with moderate/severe SG.
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S triae distensae or “stretch marks,”referred to as striae gravidarum
(SG) when they occur in pregnancy,
are a common skin problem of consid-
erable cosmetic concern to many pa-
tients. They are characterized clinically
by linear bands that are initially ery-
thematous to violaceous and gradually
fade to become skin colored or hypo-
pigmented atrophic lines that may
be thin or wide. SG occur on the ab-
domen, breasts, buttocks, hips, and
thighs and usually develop after the
24th week of gestation.1
The cause of SG remains unknownbut
clearly relates to changes in the struc-
tures that provide the skinwith its tensile
strength and elasticity. Mechanical
stretching of the skin in association with
hormonal factors has been implicated in
the pathogenesis.2-5 It has been postu-
lated that some hormones, like estrogen,
relaxin, and adrenocortical hormones,
decrease the adhesiveness between colla-
gen ﬁbers and increase ground sub-
stance, which results in the formation of
striae in areas of stretching.6 Striae may
form due to structural connective tissue
changes that include realignment and re-
duced elastin and ﬁbrillin in the dermis.7
However, some studies have shown that
although SG tend to occur in areas of
maximum skin stretching, there is no
correlation between the degree of striae
formation and the extent of body size en-
largement during pregnancy.8 A recent
study has found a correlation between
the presence of striae and pelvic relax-
ation, a condition associated with de-
creased collagen content.9 This study
was limited in that it used self-reported
data, and physical exams were not per-
formed.
The data on prevalence of SG and the
risk factors associated with their devel-
opment are scant and often contradic-
tory. It is estimated that up to 90% of
pregnant women develop SG3; however,
some authors report the prevalence to be
as low as 50%.10 Proposed risk factors for
the development of SG include family
history, race, skin type, birthweight
(BW), baseline body mass index (BMI),
age, weight gain, and poor nutrition;
however, most of these have not been
substantiated.1,3-5
In preparation for a clinical trial on
prevention of SG, we conducted a study
to determine the incidence of SG in pri-
miparous women in our population and
identify the risk factors associated with
their development. In addition to previ-
ously studied risk factors, we looked at
other factors, not studied in the past, that
may theoretically affect the risk of devel-
oping SG such has smoking history and
fetal gender.
MATERIALS AND METHODS
A cross-sectional studywas conducted at
a large private teaching hospital in
Beirut, Lebanon, after obtaining institu-
tional review board approval. All pri-
miparas with singleton gestations deliv-
ering during a 6-month period
(February-July 2005) were invited to
participate in the study irrespective of
gestational age at delivery. Women were
identiﬁed through the Delivery Suite
logbook on a daily basis.
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After obtaining written consent to
participate in the study, all eligible par-
ticipants were assessed during the post-
partum period before their discharge
from the hospital using a 22-item data
collection tool. Information was col-
lected from the medical charts about so-
cioeconomic status, gestational age at
delivery, total weight gain during preg-
nancy, current weight, fetal gender, and
birthweight. Socioeconomic status was
determined based on the third party cov-
erage with patients admitted on the ex-
pense of the Ministry of Health labelled
as low socioeconomic status and those
who had private insurance as high socio-
economic status. Patients were also
asked about the use of creams for pre-
vention of SG during pregnancy, smok-
ing history, and family history of stretch
marks. Family history of SG was consid-
ered positive if the woman’s mother
and/or sister had developed SG during
her pregnancy. Skin type was deter-
mined by interview questions based on
the Fitzpatrick classiﬁcation, which is
based on how often a person burns and
how well they tan when exposed to the
sun.11
Presence of SG on the abdomen,
thighs, and breasts was assessed by 1 of 3
researchers based on a scale developed
and validated by the research team. The
scale is based on the total surface area of
the affected body part that is covered by
SG: 25% was rated as mild, 25-50% as
moderate, and  50% as severe. The
scale provided a useful way to incorpo-
rate the number of SG as well as the
width of SG covering the affected area. In
return for their participation, women
were given a packet of brochures about
the postpartum period, breast feeding,
and newborn care.
Assuming a 50% prevalence of SG,10 a
total of 113 patientswould be required to
achieve a clinical signiﬁcance of 15% at a
power of 90% and a signiﬁcance level of
.05. The data were entered and analyzed
using SPSS 13.0 (Chicago, IL). Two dif-
ferent outcomes were considered: (1)
women with any SG (mild, moderate, or
severe) on either the abdomen, thighs, or
breasts versus those with no SG in any of
those sites; and (2) women with moder-
ate and/or severe SG in any of the 3 sites
versuswomenwhohad eithermild SGor
none. Comparing the 2 outcomes across
women’s characteristics was done by ei-
ther performing chi-square tests if the
variables were categorical or t tests if the
variables were continuous. Statistical
signiﬁcance was set at  0.05.
RESULTS
During the study period, 532 women de-
livered at the hospital. Of these, 163 were
eligible for participation in the study.
Forty-one women were discharged be-
fore it was possible to approach them,
and9werenot interested inparticipating
in the study. One woman who was eligi-
ble was not approached because her in-
fant was stillborn. Of the 112 women
that were assessed, 1 had missing infor-
mation for SG on the abdomen, thigh,
and breast and another had no SG on
abdomen and thigh but had missing in-
formation on the breast. Thus, both pa-
tients were excluded from the ﬁnal anal-
ysis.
All eligible patients who were not for-
mally assessed were compared to the
women (n 110) included in the study.
No signiﬁcant differences were found in
maternal age, socioeconomic status, ges-
tational age at delivery, fetal gender, or
birthweight.
Of the 110 women enrolled in the
study, 67 (61%) developed SG in at least
1 of the assessed sites. Fifty-three women
(48%)developed SGon the abdomen, 27
(25%) developed SG on the breasts, and
27 (25%) developed SG on the thighs
during their pregnancy. Figure 1 shows
the percentage of womenwho developed
SG at 1, 2, or all 3 sites. Of the abdominal
striae, 17 (32%) were mild, 18 (34%)
moderate, and another 18 (34%) severe.
The severity of the striae on the breasts
and thighs of the women were similar to
each other with 19 (70%) reported as
mild, 7 (26%) as moderate, and only 1
(4%) as severe. Figure 2 depicts the risk
of developing moderate/severe SG by
number of sites involved.
Most of the women in the study (93%)
delivered at term. Seven percent delivered
before 37weeksof gestationwith1woman
delivering as early as 27 weeks. Eleven of
the women (10%) delivered past 40 weeks
of gestation.Maternal age ranged between
19 and 46 years. The majority of the
women were between 24 and 34 years of
age (77%), and themeanmaternal agewas
28 years. The weight gained during the
pregnancy ranged from 3 to 33 kg with a
mean of 14.4 kg. The BW ranged between
677 and 4115 gwith ameanBWof 3143 g.
Table 1 summarizes some antenatal and
fetal characteristics in both groups.
Women who developed SG were signiﬁ-
cantly younger and had gained signiﬁ-
cantly more weight during pregnancy
compared to those who did not. BW and
gestational age at deliverywere strongly as-
sociatedwith risk of developingmoderate/
severe SG.
The predominant skin type in our
population was Fitzpatrick III (41%)
and IV (32%). Twenty percent of the
women had skin types I/II, and only 8%
had skin types V/VI. Most of the women
(88%) were nonsmokers, and 45% were
of a low socioeconomic status. Only 6%
were current smokers and continued to
FIGURE 1
Proportion of women who
developed striae gravidarum
by number of anatomic
sites involved
FIGURE 2
Proportion of women with
moderate or severe striae
gravidarum by number of
anatomic sites involved
www.AJOG.org Obstetrics Research
JANUARY 2007 American Journal of Obstetrics & Gynecology 62.e2
smoke during their pregnancy, and 7%
had smoked in the past but were no
longer smoking at diagnosis of preg-
nancy. Sixty-seven women (61%) had
used a cream or lotion during their preg-
nancy in an attempt to avoid the devel-
opment of SG, and 19 (17%) had used
more than 1 creamor lotion. There was a
large variation in the types of creams
used. The most commonly used prod-
ucts were cocoa butter (11%), baby oil
(10%), and almond oil (5%). Sixty-ﬁve
(59%) of the infants delivered were
males and 47 (43%) of them were fe-
males. No relationship was noted be-
tween skin type, socioeconomic status,
smoking, cream use, fetal gender, or
family history and the risk of developing
SG. However, women with family his-
tory of SG were more likely to develop
moderate/severe SG than were those
with no family history of SG. These ﬁnd-
ings are summarized in Table 2.
COMMENT
This study provides a clinical assessment
of the prevalence of SG and associated
risk factors in a cohort of racially homo-
geneous women at a single tertiary-care
referral center. The evaluation was based
on a new scoring system that was devel-
oped by the researchers. This is 1 of the
few studies in which SG were quantiﬁed
by clinical assessment rather than relying
on the woman’s own evaluation of her
SG. To the best of our knowledge, our
study is the only study that evaluated SG
on the breasts and thighs and not merely
the abdomen as in previously published
studies in the literature. This was con-
ﬁrmed by a MEDLINE search from 1966
to March 2006, using the keywords
“striae gravidarum,” “stretchmark,” and
“pregnancy.” Our ﬁnding that 24% of
women developed SG on their thighs or
breasts shows that these areas are also
signiﬁcantly affected by SG.
We found that the prevalence of SG is
60%, consistent with previous reported
ﬁgures.1,5 SG have a predilection to the
abdomen, the site of involvement in 47%
of the women; 24% had SG on the thighs
and/or breasts. The correlation we iden-
tiﬁed between weight gain during preg-
nancy and BW and the development of
SG are consistent with the ﬁndings by
Davey.4 Although gestational age at de-
livery and BW were similar in those who
developed SG and those who did not,
both BW and gestational age at delivery
were signiﬁcantly larger for those who
developed more severe SG. These factors
are all probably interrelated and are re-
lated to some extent to the degree of
stretching of the skin. Thomas et al noted
that women with higher BMI and larger
babies have more stretch marks.5
Similar to Thomas et al,5 we found
that younger women were more likely to
develop SG, though this ﬁnding is not
consistent with other studies.4
Although we did not ﬁnd that family
history of SGwas signiﬁcantly correlated
with the development of SG, we did ﬁnd
that women with a positive family his-
tory of SG were more likely to develop
moderate/severe SG, suggesting that ge-
netic factors do play a role in the devel-
opment of SG. The other study that as-
sessed the role of family history found a
strong relationship between family his-
tory of SG and the risk of their develop-
ment. However, that study was a volun-
tary and self-administered questionnaire
that did not take into account factors like
maternal age, number of births, and time
elapsed since the delivery date.1
The literature on the association be-
tween race and risk of the development
of SG is conﬂicting with some research-
ers ﬁnding that nonwhites were more
likely to develop SG than white women,1
while others found that women with
lighter skin were more likely to develop
SG.12 Unfortunately, our study popula-
tionwas too racially homogeneous to de-
termine any differences with regard to
SG risk related to skin type.
We felt it would be worthwhile to in-
vestigate the effects of smoking and fe-
tal gender, mostly due to the theoreti-
cal effect of tobacco and fetal sex
hormones on SG development since
both are known to affect connective
tissue properties. However, the pro-
portion of smokers in our cohort was
too small to show any difference with
regard to SG development. We found
that fetal gender did not correlate with
SG development.
A large proportion of our population
was using 1 or more creams/lotions in
an attempt to prevent the development
of SG; however, we found no correla-
tion between cream use and SG devel-
opment. In 1972, Davey found that the
use of oil and massage signiﬁcantly re-
duced the likelihood of SG develop-
ment.4 The nature of our study makes
it difﬁcult to draw any conclusions re-
TABLE 1
Distribution of striae gravidarum by age (maternal and gestational) and weight (maternal and fetal)
Presence of SG Moderate/Severe SG
Yes
(n  67)
No
(n  43) P value
Yes
(n  42)
No
(n  68) P value
Maternal age (y) 26.5 4.5 30.5  4.6 .001* 26.2  4.1 29.2  5.1 .002*
................................................................................................................................................................................................................................................................................................................................................................................
Gestational age (wk) 39.0 1.8 38.4  2.7 .202 39.4 1.3 38.4  2.5 .015*
................................................................................................................................................................................................................................................................................................................................................................................
Weight gained (kg) 15.6 3.9 12.5  4.5 .001* 16.1  3.9 13.3  4.4 .001*
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight (g) 3230  46 3020  59 .050 3300 35 3040  59 .010*
................................................................................................................................................................................................................................................................................................................................................................................
Data presented as mean  standard deviation.
SG, striae gravidarum.
* Statistically signiﬁcant.
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garding a possible advantage or role of
some of the creams utilized. It is very
likely that users of lotions/creams
started to apply these topical treat-
ments after they noted that they were
developing SG in the hope of minimiz-
ing their appearance.
The appearance of SG may be inﬂu-
enced by population genetics. If that is
the case, the signiﬁcance level () should
probably be set to lower levelswhichmay
affect our results. Genetic studies to es-
tablishwhether such a linkage exists have
already been proposed to clarify this is-
sue.13
Pregnant women often request in-
formation regarding their risks of de-
veloping SG and means to prevent
their appearance during their prenatal
visits. Our ﬁndings can help physicians
answer some of these questions when
counseling patients about their risk of
developing SG. Although some of the
factors associated with SG are not
modiﬁable (ie, age and family history),
other factors such as weight gain dur-
ing pregnancy are. Future research
should focus on preventive methods
that may reduce the likelihood of SG
development. More speciﬁcally the
prophylactic use of creams and lotions
should be further investigated to deter-
mine once and for all if these treat-
ments have any beneﬁt. f
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